Changes in Cost-Effectiveness for Chronic Hepatitis C Virus Pharmacotherapy: The Case for Continuous Cost-Effectiveness Analyses

BACKGROUND: Cost-effectiveness evaluations for hepatitis C virus (HCV) treatments have been published frequently, but new products with significant cost and effectiveness differences make these analyses obsolete. How valuable are economic models for a fixed time period in a dynamic market? OBJECTIVE...

Descripción completa

Detalles Bibliográficos
Autores principales: Mattingly, T. Joseph, Love, Bryan L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391261/
https://www.ncbi.nlm.nih.gov/pubmed/32584675
http://dx.doi.org/10.18553/jmcp.2020.26.7.879

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391261/
https://www.ncbi.nlm.nih.gov/pubmed/32584675
http://dx.doi.org/10.18553/jmcp.2020.26.7.879

Ejemplares similares